Prediction of Upgrading in Clinically Insignificant Prostate Cancer Patients Undergoing Radical Prostatectomy: The Value of Ga-68-PSMA PET/CT.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: The International Society of Urological Pathology (ISUP) grade group(GG) 1 by biopsy (bISUP GG 1) who underwent Ga-68-PSMA PET were reviewed
I · Intervention 중재 / 시술
radical prostatectomy (RP) for clinically insignificant prostate cancer (ciPCa)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Ga-68-PSMA PET/CT was found to be a potentially useful imaging biomarker for predicting pathological upgrading from combined systematic biopsy and mpMRI- targeted biopsy to RP. [ADVANCES IN KNOWLEDGE] For patients with ciPCa, there is a high likelihood of risk reclassification if they have PI-RADS 4-5 score and SUVmax higher than 4.6 on Ga-68-PSMA PET/CT.
OpenAlex 토픽 ·
Prostate Cancer Diagnosis and Treatment
Prostate Cancer Treatment and Research
Medical Imaging Techniques and Applications
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[OBJECTIVES] To evaluate the role of clinical and pathological variables, multiparametric magnetic resonance imaging (mpMRI), and Ga-68-PSMA PET/CT in prediction upgrading in patients who underwent ra
- p-value p = 0.002
- p-value p = 0.007
- 95% CI 1.124-10.007
- OR 3.354
APA
Mert Hamza Özbilen, Erkin Karaca, et al. (2026). Prediction of Upgrading in Clinically Insignificant Prostate Cancer Patients Undergoing Radical Prostatectomy: The Value of Ga-68-PSMA PET/CT.. The British journal of radiology. https://doi.org/10.1093/bjr/tqag085
MLA
Mert Hamza Özbilen, et al.. "Prediction of Upgrading in Clinically Insignificant Prostate Cancer Patients Undergoing Radical Prostatectomy: The Value of Ga-68-PSMA PET/CT.." The British journal of radiology, 2026.
PMID
42001221 ↗
Abstract 한글 요약
[OBJECTIVES] To evaluate the role of clinical and pathological variables, multiparametric magnetic resonance imaging (mpMRI), and Ga-68-PSMA PET/CT in prediction upgrading in patients who underwent radical prostatectomy (RP) for clinically insignificant prostate cancer (ciPCa).
[METHODS] Patients with The International Society of Urological Pathology (ISUP) grade group(GG) 1 by biopsy (bISUP GG 1) who underwent Ga-68-PSMA PET were reviewed. 38 who did not upgrade after RP were defined as group 1, and 37 who were upgraded after RP were defined as group 2.
[RESULTS] In patients with bISUP GG 1, the upgrade detection rate of the ISUP GG on RP material was 49.3%. PI-RADS 3, 4, and 5 scores were 71.1%, 18.4%, and 2.6% in group 1, respectively, whereas 51.4%, 18.9%, and 29.7% in group 2, respectively (p = 0.002). Mean index lesion diameter on mpMRI (p = 0.007) were found to be higher in patients who upgraded. The SUVmax detected on Ga-68-PSMA PET/CT was 4.65 in group 1 and 7 in group 2 (p = 0.003). ROC curve analysis provided a cut-off value of 4.6 g/mL for the SUVmax that would predict upgrading. PI-RADS 4-5 lesions on mpMRI (OR : 3.354,95% CI : 1.124-10.007, p = 0.030) and SUVmax ≥ 4.6 on PSMA PET/CT (OR : 6.113,95%CI : 1.893-19.875, p = 0.002) were found to be predictors for upgrading in multivariate analysis.
[CONCLUSIONS] Ga-68-PSMA PET/CT was found to be a potentially useful imaging biomarker for predicting pathological upgrading from combined systematic biopsy and mpMRI- targeted biopsy to RP.
[ADVANCES IN KNOWLEDGE] For patients with ciPCa, there is a high likelihood of risk reclassification if they have PI-RADS 4-5 score and SUVmax higher than 4.6 on Ga-68-PSMA PET/CT.
[METHODS] Patients with The International Society of Urological Pathology (ISUP) grade group(GG) 1 by biopsy (bISUP GG 1) who underwent Ga-68-PSMA PET were reviewed. 38 who did not upgrade after RP were defined as group 1, and 37 who were upgraded after RP were defined as group 2.
[RESULTS] In patients with bISUP GG 1, the upgrade detection rate of the ISUP GG on RP material was 49.3%. PI-RADS 3, 4, and 5 scores were 71.1%, 18.4%, and 2.6% in group 1, respectively, whereas 51.4%, 18.9%, and 29.7% in group 2, respectively (p = 0.002). Mean index lesion diameter on mpMRI (p = 0.007) were found to be higher in patients who upgraded. The SUVmax detected on Ga-68-PSMA PET/CT was 4.65 in group 1 and 7 in group 2 (p = 0.003). ROC curve analysis provided a cut-off value of 4.6 g/mL for the SUVmax that would predict upgrading. PI-RADS 4-5 lesions on mpMRI (OR : 3.354,95% CI : 1.124-10.007, p = 0.030) and SUVmax ≥ 4.6 on PSMA PET/CT (OR : 6.113,95%CI : 1.893-19.875, p = 0.002) were found to be predictors for upgrading in multivariate analysis.
[CONCLUSIONS] Ga-68-PSMA PET/CT was found to be a potentially useful imaging biomarker for predicting pathological upgrading from combined systematic biopsy and mpMRI- targeted biopsy to RP.
[ADVANCES IN KNOWLEDGE] For patients with ciPCa, there is a high likelihood of risk reclassification if they have PI-RADS 4-5 score and SUVmax higher than 4.6 on Ga-68-PSMA PET/CT.